Skip to Main Content

Clinical Trials

November 2018

Here is a brief synopsis of clinical research studies available in the Alzheimer’s Disease Research Unit. Please call us at (203) 764-8100 if you would like more information about any of these studies. Please call us at (203) 764-8100 if you would like more information about any of these studies. Interested patients/caregivers are also more than welcome to call us if they are interested in participating in any of our research studies or would like more information.

Caregiver Support Group

In addition to our clinical research studies, we offer a free monthly support group for caregivers of AD patients, whether or not they are participating in our research studies. Interested caregivers can call (203) 764-8100 and ask for Susan.

Treatment Studies

Enrolling

Aducanumab for Early Alzheimer’s Disease
Aducanumab is a human monoclonal antibody that is administered by intravenous infusion and is directed against the amyloid-β protein. This is a 2-year, placebo-controlled, Phase 3 study designed to evaluate the safety and efficacy of aducanumab in individuals with early Alzheimer’s disease (33 clinic visits). Participants will be randomized to receive study drug or placebo that will be administered by intravenous infusion once four weeks (20 infusions; 67% probability of receiving active study medication). Subjects will have 8 brain MRI scans and one PET scan provided with study participation. Subjects may also participate in an optional PET substudy and an optional cerebrospinal fluid substudy. After the 2-year placebo-controlled period, participants will have the option of entering a 2-year long-term extension of the study. Permits concurrent treatment with cholinesterase inhibitors and/or memantine. (MMSE 24-30, inclusive). HIC# 1505015817

JNJ-54861911 for Individuals at Risk for Alzheimer’s Disease
A stage of “preclinical Alzheimer’s disease” has recently been defined based on biomarker evidence of amyloid-β pathology before the stage of clinical symptoms. Clinically “normal” older individuals with elevated Aβ pathology (by PET scan or cerebrospinal fluid) are at increased risk for cognitive decline and progression to Alzheimer’s dementia. JNJ-54861911 is a β-site amyloid protein cleaving enzyme (BACE1) inhibitor with the potential to inhibit the synthesis of β-amyloid and thereby to slow the clinical progression of Alzheimer’s disease. This is a 4.5-year, placebo-controlled, Phase 2b/3 study designed to evaluate the efficacy of JNJ-54861911 in individuals who are asymptomatic and at risk for Alzheimer’s disease symptoms. During the double-blind period, participants will be randomized to receive study drug (5 mg or 25 mg) or placebo that will be administered orally (67% probability of receiving active study medication). Subjects will have up to 7 brain MRI scans and may have up to 3 PET scans and up to 3 lumbar punctures provided with study participation. HIC# 1608018299

CAD106 and CNP520 for Individuals at Risk for Alzheimer’s Disease
Clinically “normal” older individuals who are homozygous for APOE4 are at particularly high risk of developing symptoms of Alzheimer’s disease. CAD106 is an active vaccine against amyloid-β that is administered by intramuscular injection. CNP520 is an orally active BACE-1 inhibitor. This is a 5 to 8-year, placebo-controlled, Phase 2/3 study designed to evaluate the safety and efficacy of CAD106 and CNP520 in individuals who are APOE4 homozygotes age 60-75 years. Subjects in Group 1 will be randomized to receive either CAD106 or placebo as an intramuscular (IM) injection once every 13 weeks (five in eight chance—or 63% probability—of receiving active CAD106). Subjects in Group 2 will be randomized to receive either CNP520 or placebo as an oral medication taken daily (three in five chance—or 60% probability—of receiving active CNP520). Subjects will be required to have 7-10 brain MRI scans and 2 18F-florbetapir PET scans provided with study participation. (MMSE 24-30, inclusive). HIC# 1601017111

CNP520 for Individuals at Risk for Alzheimer’s Disease
Clinically “normal” older individuals who are have at least one APOE4 allele may be at a higher risk of developing symptoms of Alzheimer’s disease. CNP520 is an orally active BACE-1 inhibitor that is being tested for safety and efficacy in subjects at risk for the onset of symptoms of Alzheimer’s disease. This is a 5 to 8-year, placebo-controlled, Phase 2/3 study designed to evaluate the safety and efficacy of CNP520 in individuals who have at least one APOE4 allele and are age 60-75 years. Subjects who have only one APOE4 allele will also need evidence of elevated brain amyloid for study eligibility. Subjects will be randomized to receive either 15 mg or 50 mg of CNP520 or placebo as an oral medication taken daily (three in five chance—or 60% probability—of receiving active CNP520). Subjects will be required to have 8-11 brain MRI scans and 1 18F-florbetapir PET scan provided with study participation. (MMSE 24-30, inclusive). HIC# 2000021334

Crenezumab for Prodromal to Mild Alzheimer’s Disease
Crenezumab is a humanized monoclonal antibody that binds to all potentially toxic forms of Aβ, including monomers, oligomers, and fibrils. Because crenezumab is a human IgG4 backbone antibody, it has reduced Fcγ receptor binding affinity compared with human IgG1 or IgG2, which may result in a more favorable safety profile. This is a 2-year, placebo-controlled, Phase 3 study designed to evaluate the safety and efficacy of crenezumab. Participants will be randomized to receive study drug or placebo that will be administered by intravenous infusion every 4 weeks (50% probability of receiving active study medication). Subjects will have 7 brain MRI scans, up to 3 PET scans, and up to 3 lumbar punctures provided with study participation. Permits concurrent treatment with cholinesterase inhibitors and/or memantine. (MMSE ≥ 22). HIC# 1601017095

LY3314814 for Mild Alzheimer’s Disease
LY3314814 is a BACE1 inhibitor that may impact the production of β-amyloid to slow the progression of Alzheimer’s disease. This phase 3 study includes a 78-week double-blind, placebo-controlled period and a 78-week delayed-start period designed to evaluate the efficacy of LY3314814 in individuals with mild Alzheimer’s disease. During the 78-week double-blind period, participants will be randomized to receive study drug (20 mg or 50 mg) or placebo that will be administered orally (67% probability of receiving active study medication). During the 78-week delayed-start period, participants will receive LY3314814 20 mg or 50 mg. Subjects will have up to 4 brain MRI scans and up to 3 PET scans provided with study participation, along with the option for 7 additional PET scans. Permits concurrent treatment with cholinesterase inhibitors and/or memantine. (MMSE 20-26, inclusive). HIC# 1605017755

Aerobic Exercise for Mild Cognitive Impairment
This is an 18-month, Phase 3, randomized study designed to evaluate the efficacy of aerobic exercise in individuals with mild cognitive impairment (5 clinic visits). Participants will be randomized to moderate/high intensity aerobic training or stretching/balance/range of motion training (50% probability of being assigned to each training condition). Subjects will exercise at local YMCAs four (4) times per week for 18 months. During the first 12 months of the study, two of the four weekly sessions will be supervised by a study-certified YMCA trainer. In the final 6 months, participants will continue to complete their assigned exercise program at the YMCA without supervision. Subjects will have two (2) brain MRI scans provided with study participation. Subjects may also participate in an optional cerebrospinal fluid substudy (2 lumbar punctures). Permits concurrent treatment with cholinesterase inhibitors. (MMSE ≥ 24). HIC1605017787

Methylphenidate for Apathy in Dementia
Apathy is one of the most prevalent and challenging neuropsychiatric symptoms in Alzheimer’s disease. Convergent evidence has suggested that apathy in Alzheimer’s disease is related to disruptions in the brain’s dopaminergic system, and two small pilot trials have suggested a benefit of methylphenidate for this syndrome. This is a 6-month, placebo-controlled, phase 3 study to examine the efficacy and safety of methylphenidate as treatment for clinically significant apathy in individuals with Alzheimer’s disease (7 clinic visits). Subjects will be randomized to receive study drug or placebo twice daily for 6 months (50% probability of receiving active study medication). Permits concurrent treatment with cholinesterase inhibitors and/or memantine. (MMSE 10-28, inclusive). HIC# 1503015481

Gantenerumab or Solanezumab for Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease
Mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) are associated with autosomal dominant Alzheimer’s disease. This study targets individuals who are either known to have a disease-causing mutation or who are at risk for such a mutation (the child or sibling of a proband with a known mutation) and unaware of their genetic status. Gantenerumab and solanezumab are monoclonal antibodies that are directed against the amyloid-β protein. This is a 2-year, double-blind, placebo-controlled, Phase II/III study designed to assess the safety, tolerability, and biomarker efficacy of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease. Subjects will be randomized to receive gantenerumab 225mg, solanezumab 400 mg, or placebo as a subcutaneous (SC) injection or intravenous (IV) infusion once every 4 weeks for 100 weeks (35 visits total). Subjects who do not carry a disease-causing mutation will be assigned to the placebo group within each treatment arm. Subjects who do carry such a mutation will be randomized in a 3:1 ratio to receive the active drug (solanezumab or gantenerumab) (75% probability of receiving active drug; 25% probability of receiving placebo). Subjects and research staff will remain blinded to the results of genetic testing and also to treatment assignment. Subjects will be required to have 9 brain MRI scans, 8 PET scans, and 3 lumbar punctures during the study. Permits concurrent treatment with cholinesterase inhibitors and memantine. HIC# 1308012526

CT1812 for Mild to Moderate Alzheimer’s disease
CT1812 is a highly brain penetrant novel sigma-2/PGRMC1 antagonist molecule that may prevent and displace the binding of Aβ oligomers to neuronal synapses, thereby slowing the progression of Alzheimer’s disease. This is an 8-month, placebo-controlled, Phase 1b single-center trial designed to evaluate the safety and tolerability of CT1812 and to determine the effects of CT1812 on brain synaptic density in Alzheimer’s disease. During the 169-day treatment period, participants will be randomized to receive study drug (300 mg or 100 mg) or placebo that will be administered orally (66% probability of receiving active study medication). Subjects will have up to 3 brain MRI scans, up to 6 PET scans, and up to 2 lumbar punctures provided with study participation. Permits concurrent treatment with cholinesterase inhibitors and/or memantine. (MMSE 18-26, inclusive). HIC#2000022248.

MTAU9937A for Prodromal or Mild Alzheimer’s Disease
MTAU9937A is a monoclonal antibody directed against extracellular tau protein, thereby slowing the toxic spread of this protein in Alzheimer’s disease. This phase 2 study will evaluate the safety and efficacy of MTAU9937A in participants ages 50-80 years with prodromal or mild Alzheimer’s disease for 68 weeks, with the option of open-label participation for 96 weeks. Participants will be randomized to receive study drug (1500 mg, 4500 mg, or 8100 mg MTAU9937A) or placebo that will be administered intravenously (70% probability of receiving active MTAU9937A). Participants will have up to 4 brain MRI scans, up to 5 PET scans, and up to 5 optional lumbar punctures provided with study participation. Permits concurrent treatment with cholinesterase inhibitors and/or memantine, providing they have been on a stable dose at least 2 months prior to screening. (MMSE ≥20). HIC#2000022987.

BIIB092 for Prodromal or Mild Alzheimer’s Disease
BIIB092 is a monoclonal antibody directed against extracellular tau protein, thereby slowing the toxic spread of this protein in Alzheimer’s disease. This phase 2 study will evaluate the safety, tolerability, and efficacy of BIIB092 in participants ages 50-80 years with prodromal or mild Alzheimer’s disease for 76 weeks. Participants will be randomized to receive study drug (125 mg, 600 mg, or 2000 mg BIIB092) or placebo that will be administered intravenously (67% probability of receiving active BIIB092). Participants will have up to 4 brain MRI scans and up to 4 PET scans provided with study participation. Permits concurrent treatment with cholinesterase inhibitors and/or memantine, providing they have been on a stable dose at least 8 weeks prior to screening. (MMSE ≥22). HIC#2000023510.

E2609 for Early Alzheimer’s Disease
E2609 is a BACE1 inhibitor that may impact the production of β-amyloid to slow the progression of Alzheimer’s disease. This is a phase 3 study with a 24-month double-blind, placebo-controlled period designed to evaluate the efficacy of E2609 in individuals with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s dementia. Participants will be randomized to receive study drug (50 mg) or placebo that will be administered orally (50% probability of receiving active study medication). Subjects will have up to 3 brain MRI scans and up to 2 PET scans provided with study participation, along with the option for 3 additional PET scans. Permits concurrent treatment with cholinesterase inhibitors and/or memantine. (MMSE ≥ 24, inclusive). HIC #2000022087.

E2609 for Early Alzheimer’s Disease
E2609 is a BACE1 inhibitor that may impact the production of β-amyloid to slow the progression of Alzheimer’s disease. This is a phase 3 study with a 24-month double-blind, placebo-controlled period designed to evaluate the efficacy of E2609 in individuals with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s dementia. Participants will be randomized to receive study drug (50 mg) or placebo that will be administered orally (50% probability of receiving active study medication). Subjects will have up to 3 brain MRI scans and up to 2 PET scans provided with study participation, along with the option for 3 additional PET scans. Permits concurrent treatment with cholinesterase inhibitors and/or memantine. (MMSE ≥ 24, inclusive). HIC #2000022087.